JP4565087B2 - 新規なχ−コノトキシン・ペプチド（−Ｉ） - Google Patents

新規なχ−コノトキシン・ペプチド（−Ｉ） Download PDF

Info

Publication number
JP4565087B2
JP4565087B2 JP2004555869A JP2004555869A JP4565087B2 JP 4565087 B2 JP4565087 B2 JP 4565087B2 JP 2004555869 A JP2004555869 A JP 2004555869A JP 2004555869 A JP2004555869 A JP 2004555869A JP 4565087 B2 JP4565087 B2 JP 4565087B2
Authority
JP
Japan
Prior art keywords
cys
xaa1
seq
lys leu
xaa3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004555869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006523181A (ja
JP2006523181A5 (enExample
Inventor
ルイス，リチャード，ジェイムズ
アレウッド，ポール，フランシス
アレウッド，ディアン
パラント，エルカ
Original Assignee
ゼノム リミティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゼノム リミティッド filed Critical ゼノム リミティッド
Publication of JP2006523181A publication Critical patent/JP2006523181A/ja
Publication of JP2006523181A5 publication Critical patent/JP2006523181A5/ja
Application granted granted Critical
Publication of JP4565087B2 publication Critical patent/JP4565087B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2004555869A 2002-12-02 2003-12-02 新規なχ−コノトキシン・ペプチド（−Ｉ） Expired - Fee Related JP4565087B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43030602P 2002-12-02 2002-12-02
PCT/AU2003/001605 WO2004050690A1 (en) 2002-12-02 2003-12-02 NOVEL χ-CONOTOXIN PEPTIDES (-I)

Publications (3)

Publication Number Publication Date
JP2006523181A JP2006523181A (ja) 2006-10-12
JP2006523181A5 JP2006523181A5 (enExample) 2006-11-24
JP4565087B2 true JP4565087B2 (ja) 2010-10-20

Family

ID=32469446

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004555869A Expired - Fee Related JP4565087B2 (ja) 2002-12-02 2003-12-02 新規なχ−コノトキシン・ペプチド（−Ｉ）

Country Status (13)

Country Link
US (1) US7851444B2 (enExample)
EP (1) EP1572725B1 (enExample)
JP (1) JP4565087B2 (enExample)
AT (1) ATE547424T1 (enExample)
AU (1) AU2003302609B9 (enExample)
CA (1) CA2508129C (enExample)
CY (1) CY1112839T1 (enExample)
DK (1) DK1572725T3 (enExample)
ES (1) ES2383358T3 (enExample)
NZ (1) NZ540518A (enExample)
PT (1) PT1572725E (enExample)
SI (1) SI1572725T1 (enExample)
WO (1) WO2004050690A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP627498A0 (en) * 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
WO2004050688A1 (en) * 2002-12-02 2004-06-17 Xenome Ltd NOVEL χ-CONOTOXIN PEPTIDES (-II)
US8062623B2 (en) * 2004-10-15 2011-11-22 Velocys Stable, catalyzed, high temperature combustion in microchannel, integrated combustion reactors
US20070154360A1 (en) * 2005-10-13 2007-07-05 Velocys Inc. Microchannel apparatus comprising a platinum aluminide layer and chemical processes using the apparatus
CN102752032B (zh) * 2011-04-22 2015-04-22 艾利森电话股份有限公司 同频负载均衡方法及其设备
CA2986704C (en) * 2015-05-22 2022-03-01 Clemson University Research Foundation Conotoxin peptides for use in biofouling deterrence
CN119462881A (zh) * 2024-12-20 2025-02-18 深圳肽盛生物科技有限公司 μ型芋螺毒素肽及其药物组合物和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051403A (en) 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
ZA921292B (en) 1991-02-25 1993-08-23 Lilly Co Eli Treatment of lower urinary tract disorders.
CA2151741C (en) * 1991-12-30 2001-12-11 Alan Justice Methods of producing analgesia and enhancing opiate analgesia
PT789580E (pt) 1994-11-03 2002-09-30 Novartis Ag Formulacoes de ciclosporina para administracao oral com composicao simples e alta biodisponibilidade e processo para a sua producao
WO1996040064A1 (en) 1995-06-07 1996-12-19 Nexstar Pharmaceuticals, Inc. Liposomal cyclosporin formulations as agents for immunosuppression and multiple drug resistant indications
DK0835126T3 (da) 1995-06-27 2003-07-14 Elan Pharm Inc Sammensætninger og formuleringer til fremstilling af analgesimidler og til hamning af fremadskridende neuropatiske amertelidelser
TR199801641T2 (xx) 1996-02-22 1998-11-23 Neurosearch A/S Tropan t�revleri bunlar�n haz�rlanmas� ve kullan�m�
GB9614902D0 (en) 1996-07-16 1996-09-04 Rhodes John Sustained release composition
CZ288739B6 (cs) 1996-08-01 2001-08-15 Galena, A. S. Cyklosporin obsahující léčivé přípravky
JP2001505878A (ja) 1996-11-18 2001-05-08 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション 心臓血管剤としてのコノトキシンペプチドＩｍＩおよびＭＩＩの使用
EP0981515B1 (en) 1997-05-14 2003-08-27 Neurosearch A/S Piperidine derivatives as neurotransmitter re-uptake inhibitors
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
US6767896B1 (en) * 1999-01-29 2004-07-27 Cognetix, Inc. Conotoxin peptides
WO2000044769A1 (en) * 1999-01-29 2000-08-03 University Of Utah Research Foundation Conotoxin peptides
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
WO2002060923A2 (en) * 2001-01-29 2002-08-08 Cognetix, Inc. B-superfamily conotoxins
WO2002064740A2 (en) * 2001-02-09 2002-08-22 Cognetix, Inc. Cone snail peptides
WO2004050688A1 (en) * 2002-12-02 2004-06-17 Xenome Ltd NOVEL χ-CONOTOXIN PEPTIDES (-II)

Also Published As

Publication number Publication date
CA2508129A1 (en) 2004-06-17
DK1572725T3 (da) 2012-06-18
ATE547424T1 (de) 2012-03-15
WO2004050690A1 (en) 2004-06-17
EP1572725B1 (en) 2012-02-29
SI1572725T1 (sl) 2012-08-31
JP2006523181A (ja) 2006-10-12
NZ540518A (en) 2006-12-22
EP1572725A4 (en) 2008-09-24
HK1080870A1 (en) 2006-05-04
AU2003302609A1 (en) 2004-06-23
US20060142201A1 (en) 2006-06-29
AU2003302609B2 (en) 2008-03-20
AU2003302609B9 (en) 2008-05-15
CA2508129C (en) 2012-06-26
ES2383358T3 (es) 2012-06-20
PT1572725E (pt) 2012-05-28
EP1572725A1 (en) 2005-09-14
CY1112839T1 (el) 2016-02-10
US7851444B2 (en) 2010-12-14

Similar Documents

Publication Publication Date Title
US5891849A (en) Methods and formulations for preventing progression of neuropathic pain
US20090088389A1 (en) Novel x-conotoxin peptides (-ii)
TW200902068A (en) GLP-1 peptide having sugar chain attached thereto
WO2005000339A2 (en) Melanocortin receptor 4(mc4) agonists and their uses
US20160108090A1 (en) Dynorphin a analogs with bradykinin receptors specificity for modulation of neuropathic pain
JP4565087B2 (ja) 新規なχ−コノトキシン・ペプチド（−Ｉ）
WO2017073764A1 (ja) 新規ｎｋ３受容体アゴニスト
CA2347713C (en) Contulakin-g, analogs thereof and uses therefor
US10881712B2 (en) Neuroprotective agents derived from spider venom peptides
JP2023529825A (ja) コンフォメーション化された拘束型α－ＲＧＩＡアナログ
NZ540582A (en) Chimaeric protein containing cysteine protease of liver fluke fused to hepatitis B core protein or ubiquitin, plants expressing said protein, and uses thereof as vaccine
WO2004069857A2 (en) “peptides, compositions and uses thereof”
WO2014075137A1 (en) Peptides incorporating amino-substituted lactams for treatment of retinopathy
JP2002536970A (ja) タウ−コノトキシン・ペプチド
HK1080870B (en) Chi-conotoxin peptides having a n-terminal pyroglutamic acid
HK1164340A (en) Chi-conotoxin peptides (ii)
HK1166808A (en) Chi-conotoxin peptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060929

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20090625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090811

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091013

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100428

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100601

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100621

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130813

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees